The 2021 Communications Awards have opened their doors for entry, inviting the very best in pharma communications to come forward and claim first prize.
News
NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
EC approval for Ontozry
The drug offers new hope for epilepsy patients with focal-onset seizures
Researchers link to facilitate cheaper biologics
The parties intend to develop more cost-effective ways of producing biologic medicines
Thousands to benefit from five-minute breast cancer treatment
NHS England is rolling out Roche’s new combined treatment Phesgo, which drastically cuts administration time
Twice-weekly coronavirus tests for all
Everyone in England, including those without symptoms, will be able to take a free rapid coronavirus test twice a week
PharmaTimes are proud to announce the launch of Marketer of the Year 2021
Celebrating and uncovering exceptional pharma marketing talent for nearly three decades, the Marketer of the Year competition has launched for 2021.
FDA green light for Sarclisa combo in multiple myeloma
CD38 inhibitor approved in combination with carfilzomib and dexamethasone
Cancer research in the UK faces ‘perfect storm’ of funding cuts
Experts have raised ‘serious concerns’ over government plans for UK science funding
Opdivo plus Cabometyx approved in the EU for advanced renal cancer
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial
Positive results for Pfizer/BioNTech’s COVID-19 vaccine in 12-15 year olds
The vaccine demonstrated 100% efficacy in a Phase III trial in adolescents aged 12 to 15 years old
Just 2 weeks left until INTCR 2021 closes for entry
The 2021 International Clinical Researcher of the Year competition will be closing for entry on the 16th of April.
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma
RELATIVITY-047 trial met primary endpoint of progression-free survival
Roche scores EU approval for at-home SMA treatment Evrysdi
Therapy indicated for use in SMA patients aged two months and older
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
Biologic therapy approved to treat systemic juvenile idiopathic arthritis and adult-onset Still’s disease
